Notebook

Nobel laureate David Baltimore will assume the presidency of the California Institute of Technology this fall. Baltimore, 59, tells The Scientist he is leaving his post as a professor of molecular biology and immunology at the Massachusetts Institute of Technology, where he has been since 1994, because Caltech is "one of the premier scientific organizations in the world." Baltimore's tenure as president of Rockefeller University in New York lasted just 18 months; he resigned in late 1991 in the

| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Nobel laureate David Baltimore will assume the presidency of the California Institute of Technology this fall. Baltimore, 59, tells The Scientist he is leaving his post as a professor of molecular biology and immunology at the Massachusetts Institute of Technology, where he has been since 1994, because Caltech is "one of the premier scientific organizations in the world." Baltimore's tenure as president of Rockefeller University in New York lasted just 18 months; he resigned in late 1991 in the midst of a furor caused by a paper (D. Weaver et al., Cell, 45:247-59, 1986) he coauthored with Thereza Imanishi-Kari, who was accused of falsifying data to obtain better results. Baltimore, who was not accused of wrongdoing, nevertheless became a lightning rod for controversy and a subject of congressional hearings for defending Imanishi-Kari, who was later cleared by an appeals panel of the U.S. Department of Health and Human Services (B. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies